Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
19. Juni 2019 07:30 ET
|
Melinta Therapeutics
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20. Februar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
02. März 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia
06. Januar 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, announced the initiation of an...
Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis
02. Juni 2015 07:30 ET
|
Melinta Therapeutics
New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more
than 150 other major food companies, retailers, and human and
animal health stakeholders at...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
19. Mai 2015 16:00 ET
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment
09. April 2015 12:02 ET
|
Melinta Therapeutics
New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of
Health-Related Quality-of-Life (HRQL) in acute bacterial skin and
skin structure infection...
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
09. Februar 2015 08:00 ET
|
Melinta Therapeutics
New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a
$30 million growth capital debt financing agreement with Hercules
Technology Growth...
Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil
08. Januar 2015 15:08 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the
largest pharmaceutical companies in Brazil, announced that...
Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae
08. September 2014 11:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results from in vitro studies that highlight the
potential of delafloxacin, an
investigational fluoroquinolone,...